naltrexone has been researched along with Bladder Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chamie, K; Faiena, I; Golla, V; Johnson, DC; Lec, PM; Lee, C; Lenis, AT; Rahman, S | 1 |
| Pan, Z; Shi, Y; So, EC; Tang, D; Tian, J; Wang, X; Wu, T; Wu, X; Yu, W; Zhang, R; Zhou, X | 1 |
2 other study(ies) available for naltrexone and Bladder Cancer
| Article | Year |
|---|---|
The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy.
Topics: Aged; Cystectomy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Postoperative Complications; Postoperative Period; Quaternary Ammonium Compounds; Retrospective Studies; Robotic Surgical Procedures; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Successive treatment with naltrexone induces epithelial-mesenchymal transition and facilitates the malignant biological behaviors of bladder cancer cells.
Topics: Animals; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Humans; MAP Kinase Signaling System; Mice; Naltrexone; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Urinary Bladder Neoplasms | 2021 |